1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT
(DATE OF EARLIEST EVENT REPORTED): JANUARY 8, 2001
ARONEX PHARMACEUTICALS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 0-20111 76-0196535
(STATE OR OTHER JURISDICTION OF (COMMISSION FILE NUMBER) (I.R.S. EMPLOYER IDENTIFICATION NO.)
INCORPORATION OR ORGANIZATION)
8707 TECHNOLOGY FOREST PLACE
THE WOODLANDS, TEXAS 77381-1191
(ADDRESS OF PRINCIPAL
EXECUTIVE OFFICES
AND ZIP CODE)
(281) 367-1666
(REGISTRANT'S TELEPHONE NUMBER,
INCLUDING AREA CODE)
2
ITEM 5. OTHER EVENTS
On January 8, 2001, Aronex Pharmaceuticals, Inc. (the "Company")
publicly disseminated a press release announcing that the U.S. Food and Drug
Administration has denied approval of the Company's New Drug Application for
ATRAGEN(R) (tretinoin liposome for injection) as a treatment for patients with
acute promyelocytic leukemia, for whom therapy with tretinoin is necessary but
for whom an intravenous administration is required. The recent ruling from the
FDA will result in the Company taking steps to reserve cash by reducing its
workforce and other operating expenses.
The foregoing description is qualified in its entirety by reference to
the Company's press release dated January 8, 2001, a copy of which is attached
hereto as Exhibit 99.1.
ITEM 7. EXHIBITS
Exhibit 99.1 -- The Company's Press Release dated January 8, 2001.
-2-
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ARONEX PHARMACEUTICALS, INC.
Date: January 9, 2001
By: /s/ TERANCE A. MURNANE
---------------------------------------
Terance A. Murnane
Controller
-3-
4
EXHIBIT INDEX
Exhibit No. Description
- ----------- -----------
Exhibit 99.1 -- The Company's Press Release dated January 8, 2001.